Centessa Pharmaceuticals plc (CNTA) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Altrincham, United Kingdom. Der aktuelle CEO ist Mario Alberto Accardi.
CNTA hat IPO-Datum 2021-05-28, 77 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $5.91B.
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company focused on discovering, developing, and delivering medicines across multiple therapeutic areas. The company's registrational pipeline includes Lixivaptan, a vasopressin V2 receptor inhibitor in Phase III development for autosomal dominant polycystic kidney disease, and SerpinPC, an activated protein C inhibitor in Phase IIa development for hemophilia A and B. Its emerging pipeline comprises innovative candidates such as LockBody immunotherapies (LB101 and LB201), ZF874 for alpha-1-antitrypsin deficiency, MGX292 for pulmonary arterial hypertension, OX2R Agonists for narcolepsy type 1, and exploratory programs including CBS001 and CBS004 targeting inflammatory and autoimmune diseases. Incorporated in 2020, Centessa is headquartered in Altrincham, United Kingdom.
